Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

• Hope S. Rugo,
• Sara M. Tolaney,
• Delphine Loirat,
• Kevin Punie,
• Aditya Bardia,
• Sara A. Hurvitz,
• Joyce O’Shaughnessy,
• Javier Cortés,
• Véronique Diéras,
• Lisa A. Carey,
• Luca Gianni,
• Martine J. Piccart,
• Sibylle Loibl,
• David M. Goldenberg,
• Quan Hong,
• Martin Olivo,
• Loretta M. Itri,
• Kevin Kalinsky

Affiliations

Hope S. Rugo

Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center

Sara M. Tolaney

Department of Medical Oncology, Dana-Farber Cancer Institute

Delphine Loirat

Department of Medical Oncology and D3i, Institut Curie

Kevin Punie

Department of General Medical Oncology, University Hospitals Leuven

Aditya Bardia

Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School

Sara A. Hurvitz

Medical Oncology, University of California, Los Angeles, Jonsson Comprehensive Cancer Center

Joyce O’Shaughnessy

Baylor University Medical Center, Texas Oncology, US Oncology

Javier Cortés

International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona

Véronique Diéras

Department of Medical Oncology, Centre Eugène Marquis

Lisa A. Carey

Department of Hematology and Oncology, University of North Carolina Lineberger Comprehensive Cancer Center

Luca Gianni

Gianni Bonadonna Foundation

Martine J. Piccart

Medical Oncology, Institute Jules Bordet

Sibylle Loibl

Department of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus

David M. Goldenberg

Department of Clinical Development, Immunomedics, Inc.

Quan Hong

Department of Clinical Development, Immunomedics, Inc.

Martin Olivo

Department of Clinical Development, Immunomedics, Inc.

Loretta M. Itri

Department of Clinical Development, Immunomedics, Inc.

Kevin Kalinsky

Columbia University Irving Medical Center